RESUMEN
BACKGROUND: The adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) in ≥60-years-olds over 1 RSV season. We evaluated efficacy and safety of 1 RSVPreF3 OA dose and of 2 RSVPreF3 OA doses given 1 year apart against RSV-LRTD over 2 RSV seasons post-dose 1. METHODS: In this phase 3, blinded trial, ≥60-year-olds were randomized (1:1) to receive RSVPreF3 OA or placebo pre-season 1. RSVPreF3 OA recipients were re-randomized (1:1) to receive a second RSVPreF3 OA dose (RSV_revaccination group) or placebo (RSV_1dose group) pre-season 2; participants who received placebo pre-season 1 received placebo pre-season 2 (placebo group). Efficacy of both vaccine regimens against RSV-LRTD was evaluated over 2 seasons combined (confirmatory secondary objective, success criterion: lower limits of 2-sided CIs around efficacy estimates >20%). RESULTS: The efficacy analysis comprised 24 967 participants (RSV_1dose: 6227; RSV_revaccination: 6242; placebo: 12 498). Median efficacy follow-up was 17.8 months. Efficacy over 2 seasons of 1 RSVPreF3 OA dose was 67.2% (97.5% CI: 48.2-80.0%) against RSV-LRTD and 78.8% (95% CI: 52.6-92.0%) against severe RSV-LRTD. Efficacy over 2 seasons of a first dose followed by revaccination was 67.1% (97.5% CI: 48.1-80.0%) against RSV-LRTD and 78.8% (95% CI: 52.5-92.0%) against severe RSV-LRTD. Reactogenicity/safety of the revaccination dose were similar to dose 1. CONCLUSIONS: One RSVPreF3 OA dose was efficacious against RSV-LRTD over 2 RSV seasons in ≥60-year-olds. Revaccination 1 year post-dose 1 was well tolerated but did not seem to provide additional efficacy benefit in the overall study population. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov: NCT04886596.
Asunto(s)
Infecciones por Virus Sincitial Respiratorio , Vacunas contra Virus Sincitial Respiratorio , Virus Sincitial Respiratorio Humano , Proteínas Virales de Fusión , Humanos , Infecciones por Virus Sincitial Respiratorio/prevención & control , Vacunas contra Virus Sincitial Respiratorio/inmunología , Vacunas contra Virus Sincitial Respiratorio/administración & dosificación , Vacunas contra Virus Sincitial Respiratorio/efectos adversos , Masculino , Femenino , Virus Sincitial Respiratorio Humano/inmunología , Anciano , Persona de Mediana Edad , Proteínas Virales de Fusión/inmunología , Anticuerpos Antivirales/sangre , Anciano de 80 o más Años , Estaciones del Año , Eficacia de las Vacunas , Método Doble Ciego , Inmunización SecundariaRESUMEN
BACKGROUND: Psychiatric comorbidity measured by screening instruments is common in patients with chronic pancreatitis (CP) but whether this accurately reflects clinical diagnosis of psychiatric comorbidity is unknown and the prevalence of psychotropic medication prescription in CP remains largely unexplored. METHODS: Adult patients (≥18 years) with definite CP were enrolled and completed the Hospital Anxiety and Depression Scale (HADS). Demographics, clinical characteristics and medications were retrieved from case report forms and the electronic health record (EHR). Clinical diagnosis of depression or anxiety was determined by presence of ICD-10 code or inclusion in the patient's EHR problem list or treatment plan. Comparisons were made between patients with and without clinical psychiatric comorbidity. RESULTS: Total of 81 patients (48, 59.3% male; mean age 57.6 ± 14.3 years) were included. Clinical diagnoses of anxiety and depression were each noted in 47 (58%) patients, with overlap in 42 (51.9%). Compared to clinical diagnoses, the sensitivity and specificity of a positive screen for anxiety (HADS >7) were 76.6% and 91.2%; for depression 55.3% and 88.2%. Patients with anxiety and/or depression were more frequently female (51.9% v 20.7%), younger (53.6 v 64.9 years), and had alcohol etiology (51.9% v 27.6%) (all p < 0.01). In those with psychiatric comorbidity, 42 (80.8%) were prescribed psychotropic medication, most commonly gabapentinoid (24, 57.1%), selective serotonin reuptake inhibitor (n = 22, 52.4%) or benzodiazepine (n = 20, 47.6%). CONCLUSIONS: Psychiatric comorbidities are common among CP patients and many receive psychotropic medications. Further studies are needed to evaluate the impact of these medications on CP symptoms.
Asunto(s)
Pancreatitis Crónica , Psicotrópicos , Adulto , Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Psicotrópicos/uso terapéutico , Comorbilidad , Ansiedad/epidemiología , Benzodiazepinas , Pancreatitis Crónica/epidemiologíaRESUMEN
BACKGROUND: Spontaneous pancreatic portal vein fistula (PPVF) - a rare complication of pancreatic inflammation - varies widely in presentation and means of diagnosis but has been previously associated with bleeding complications and mortality. A systematic review of published literature was performed to assess the frequency of outcomes. METHODS: A search of electronic databases (PubMed, Ovid MEDLINE, Scopus, EMBASE, gray literature) resulted in 1667 relevant unique manuscripts; 52 met inclusion criteria. RESULTS: A total of 74 unique (male n = 47, 63.5 %) patients were included. Mean age was 53.5 (±11.9) years. History of alcohol use was reported in 55 (74.3 %). Underlying chronic pancreatitis (CP) was present in 49 (66.2 %). In cases where presenting symptoms were reported (n = 57, 77.4 %), the most frequent were abdominal pain (63.5 %), weight loss (14.9 %), rash (12.2 %), nausea/vomiting (12.2 %), and polyarthritis (9.5 %). Computed tomography was the most common imaging modality used to confirm the diagnosis (n = 20, 27.0 %), followed by magnetic resonance cholangiopancreatography (n = 14, 18.9 %). Portal vein thrombosis was reported in 57 (77.0 %), and bleeding events (luminal, variceal, or intra-pseudocyst) were reported in 13(17.6 %) patients. Younger age was associated with higher risk of bleeding events. Mortality was reported in 12 (16.2 %) patients at any time during follow up. Older age and polyarthritis at presentation were associated with mortality. CONCLUSIONS: PPVF is a rare and potentially fatal condition, though rates of bleeding complication and death were relatively low in this population. High-quality observational studies are needed to better understand the pathophysiology and natural history of this diagnosis.
RESUMEN
BACKGROUND: Depression affects 20-30% of individuals with heart failure (HF), and it is associated with worse health outcomes independent of disease severity. One potential explanation is the adverse impact of depression on HF patients' adherence to the health behaviors needed to self-manage their condition. The aim of this study is to identify characteristics associated with lower adherence in this population, which could help to recognize individuals at higher risk and eventually tailor health behavior interventions to their needs. METHODS: Using data from a randomized, controlled, collaborative care treatment trial in 629 patients with HF and comorbid depression, we performed mixed effects logistic regression analyses to examine the cross-sectional and prospective relationships between medical and psychosocial variables and health behavior adherence, including adherence to medications, a low-sodium diet, and physician appointments. RESULTS: In cross-sectional analyses, married marital status and higher physical health-related quality of life (HRQoL) were associated with greater overall adherence (compared to married, single Odds Ratio [OR] = 0.46, 95% Confidence Interval [CI] = 0.26-0.80; other OR = 0.60, CI = 0.38-0.94; p = .012. Physical HRQoL OR = 1.02, CI = 1.00-1.04, p = .047). Prospectively, greater levels of social support were associated with improved overall adherence one year later (OR = 1.04, 95% CI = 1.00-1.08, p = .037). Social support, HF symptom severity, race and ethnicity, and age were predictors of specific types of adherence. Neither depression nor optimism was significantly associated with adherence outcomes. CONCLUSIONS: These results provide important preliminary information about risk factors for poor adherence in patients with both HF and depression, which could, in turn, contribute to the development of interventions to promote adherence in this high-risk population. TRIAL REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT02044211 ; registered 1/21/2014.
Asunto(s)
Comorbilidad , Depresión , Conductas Relacionadas con la Salud , Insuficiencia Cardíaca , Calidad de Vida , Humanos , Masculino , Femenino , Persona de Mediana Edad , Insuficiencia Cardíaca/psicología , Anciano , Estudios Transversales , Depresión/psicología , Depresión/epidemiología , Calidad de Vida/psicología , Cooperación del Paciente/estadística & datos numéricos , Cooperación del Paciente/psicología , Cumplimiento de la Medicación/estadística & datos numéricos , Cumplimiento de la Medicación/psicología , Estudios Prospectivos , Estado CivilRESUMEN
BACKGROUND: A previously reported study examined the treatment of primary care patients with at least moderate severity depressive or anxiety symptoms via an evidence-based computerized cognitive behavioral therapy (CCBT) program (Beating the Blues) and an online health community (OHC) that included a moderated internet support group. The 2 treatment arms proved to be equally successful at 6-month follow-up. OBJECTIVE: Although highly promising, e-mental health treatment programs have encountered high rates of noninitiation, poor adherence, and discontinuation. Identifying ways to counter these tendencies is critical for their success. To further explore these issues, this study identified the primary care patient characteristics that increased the chances patients would not initiate the use of an intervention, (ie, not try it even once), initiate use, and go on to discontinue or continue to use an intervention. METHODS: The study had 3 arms: one received access to CCBT (n=301); another received CCBT plus OHC (n=302), which included a moderated internet support group; and the third received usual care (n=101). Participants in the 2 active intervention arms of the study were grouped together for analyses of CCBT use (n=603) because both arms had access to CCBT, and there were no differences in outcomes between the 2 arms. Analyses of OHC use were based on 302 participants who were randomized to that arm. RESULTS: Several baseline patient characteristics were associated with failure to initiate the use of CCBT, including having worse physical health (measured by the Short Form Health Survey Physical Components Score, P=.01), more interference from pain (by the Patient-Reported Outcomes Measurement Information System Pain Interference score, P=.048), less formal education (P=.02), and being African American or another US minority group (P=.006). Characteristics associated with failure to initiate use of the OHC were better mental health (by the Short Form Health Survey Mental Components Score, P=.04), lower use of the internet (P=.005), and less formal education (P=.001). Those who initiated the use of the CCBT program but went on to complete less of the program had less formal education (P=.01) and lower severity of anxiety symptoms (P=.03). CONCLUSIONS: This study found that several patient characteristics predicted whether a patient was likely to not initiate use or discontinue the use of CCBT or OHC. These findings have clear implications for actionable areas that can be targeted during initial and ongoing engagement activities designed to increase patient buy-in, as well as increase subsequent use and the resulting success of eHealth programs. TRIAL REGISTRATION: ClinicalTrials.gov NCT01482806; https://clinicaltrials.gov/study/NCT01482806.
Asunto(s)
Terapia Cognitivo-Conductual , Depresión , Humanos , Depresión/terapia , Ansiedad/terapia , Internet , Dolor , Atención Primaria de SaludRESUMEN
BACKGROUND: Active surveillance pharmacovigilance is an emerging approach to identify medications with unanticipated effects. We previously developed a framework called pharmacopeia-wide association studies (PharmWAS) that limits false positive medication associations through high-dimensional confounding adjustment and set enrichment. We aimed to assess the transportability and generalizability of the PharmWAS framework by using medical claims data to reproduce known medication associations with Clostridioides difficile infection (CDI) or gastrointestinal bleeding (GIB). METHODS: We conducted case-control studies using Optum's de-identified Clinformatics Data Mart Database of individuals enrolled in large commercial and Medicare Advantage health plans in the United States. Individuals with CDI (from 2010 to 2015) or GIB (from 2010 to 2021) were matched to controls by age and sex. We identified all medications utilized prior to diagnosis and analysed the association of each with CDI or GIB using conditional logistic regression adjusted for risk factors for the outcome and a high-dimensional propensity score. FINDINGS: For the CDI study, we identified 55,137 cases, 220,543 controls, and 290 medications to analyse. Antibiotics with Gram-negative spectrum, including ciprofloxacin (aOR 2.83), ceftriaxone (aOR 2.65), and levofloxacin (aOR 1.60), were strongly associated. For the GIB study, we identified 450,315 cases, 1,801,260 controls, and 354 medications to analyse. Antiplatelets, anticoagulants, and non-steroidal anti-inflammatory drugs, including ticagrelor (aOR 2.81), naproxen (aOR 1.87), and rivaroxaban (aOR 1.31), were strongly associated. INTERPRETATION: These studies demonstrate the generalizability and transportability of the PharmWAS pharmacovigilance framework. With additional validation, PharmWAS could complement traditional passive surveillance systems to identify medications that unexpectedly provoke or prevent high-impact conditions. FUNDING: U.S. National Institute of Diabetes and Digestive and Kidney Diseases.
Asunto(s)
Clostridioides difficile , Infecciones por Clostridium , Hemorragia Gastrointestinal , Farmacovigilancia , Humanos , Infecciones por Clostridium/epidemiología , Infecciones por Clostridium/etiología , Infecciones por Clostridium/tratamiento farmacológico , Estudios de Casos y Controles , Masculino , Hemorragia Gastrointestinal/inducido químicamente , Hemorragia Gastrointestinal/epidemiología , Hemorragia Gastrointestinal/etiología , Femenino , Anciano , Persona de Mediana Edad , Antibacterianos/efectos adversos , Antibacterianos/uso terapéutico , Estados Unidos/epidemiología , Factores de Riesgo , Adulto , Anciano de 80 o más AñosRESUMEN
Transcriptomic studies of marine organisms are still in their infancy. A partial, subtracted expressed sequence tag (EST) library of the Caribbean octocoral Erythropodium caribaeorum and the sea fan Gorgonia ventalina has been analyzed in order to find novel genes or differences in gene expression related to potential secondary metabolite production or symbioses. This approach entails enrichment for potential non-housekeeping genes using the suppression subtractive hybridization (SSH) polymerase chain reaction (PCR) method. More than 500 expressed sequence tags (ESTs) were generated after cloning SSH products, which yielded at least 53 orthologous groups of proteins (COGs) and Pfam clusters, including transcription factors (Drosophila Big Brother), catalases, reverse transcriptases, ferritins and various hypothetical protein sequences. A total of 591 EST sequences were deposited into GenBank [dbEST: FL512138 - FL512331, GH611838, and HO061755-HO062154]. The results represent proof of concept for enrichment of unique transcripts over housekeeping genes, such as actin or ribosomal genes, which comprised approximately 17 percent of the total dataset. Due to the gene and sequence diversity of some ESTs, such sequences can find utility as molecular markers in current and future studies of this species and other soft coral biogeography, chemical ecology, phylogenetics, and evolution.
Asunto(s)
Animales , ADN Complementario/análisis , ADN Complementario/fisiología , Antozoos/genética , Antozoos/química , /análisis , Reacción en Cadena de la Polimerasa/métodosRESUMEN
O Brasil tem sido considerado um país em transiçäo nutricional em razäo dos recentes aumentos na prevalência de obesidade e doenças crônicas na classe média, sendo importante identificar os fatores que influenciam as preferências nutricionais desse grupo. Foi realizado estudo com estudantes de classe média de um colégio secundário, particular, em Manaus, AM, Brasil. Com o objetivo de determinar a disponibilidade e a acessibilidade das merendas e analisar as atitudes e preferências dos estudantes e a influência de vários fatores na escolha de merendas nutritivas. O estudo incluiu quatro fases: (a) discussäo em um grupo de especialistas em nutriçäo sobre a disponibilidade e acessibilidade das merendas em Manaus; (b) inquérito junto a um grupo dos adolescentes (n=63) sobre suas preferências e hábitos nutricionais; (c) inquérito junto a supermercado selecionado para identificar a disponibilidade e acessibilidade das merendas preferidas; (d) um grupo acompanhado de um subamostra dos adolescentes (n=55) para identificar as preferências e atitudes sobre o custo e disponibilidade das merendas. Foi constatado que os estudantes possuíam condiçöes financeiras para comprar merendas e que as merendas nutritivas näo custam mais do que as näo nutritivas. A preferência dos adolescentes foi por merendas näo nutritivas. Os fatores que, principalmente, influenciam na escolha originam-se da família e da televisäo. As implicaçöes para futuras pesquisas e programas nutricionais säo discutidos, recomendando-se campanha de educaçäo nutricional para famílias, visto a importância desta na escolha de merendas entre esses adolescentes.
Asunto(s)
Adolescente , Clase Social , Nutrición del Adolescente/fisiología , Preferencias Alimentarias , Brasil , Obesidad/epidemiologíaRESUMEN
El glaucoma, la segunda causa más frecuente de amaurosis en todo el mundo, es una enfermedad crónica, incurable. El objetivo principal del tratamiento médico es preservar la visión mediante la reducción de los valores de la presión intraocular (PIO). Actualmente se utiliza una variedad de agentes que producen hipotensión ocular, pero numerosos pacientes requieren más de un fármaco para lograr la disminución suficiente de la PIO. Esas combinaciones a menudo implican esquemas complejos de administración, con la consiguiente dificultad para su cumplimiento por parte de los pacientes; tales inconvenientes pueden obviarse con el uso de formulaciones combinadas en proporción preestablecida. La solución oftálmica que contiene la combinación en proporción fija (CPF) de latanoprost (una prostaglandina) al 0.005 y timolol (un betabloqueante) al 0.5(AU)
Asunto(s)
Humanos , Glaucoma de Ángulo Abierto/tratamiento farmacológico , Presión Intraocular/efectos de los fármacos , Combinación de Medicamentos , Prostaglandinas F Sintéticas/farmacología , Soluciones OftálmicasRESUMEN
El glaucoma, la segunda causa más frecuente de amaurosis en todo el mundo, es una enfermedad crónica, incurable. El objetivo principal del tratamiento médico es preservar la visión mediante la reducción de los valores de la presión intraocular (PIO). Actualmente se utiliza una variedad de agentes que producen hipotensión ocular, pero numerosos pacientes requieren más de un fármaco para lograr la disminución suficiente de la PIO. Esas combinaciones a menudo implican esquemas complejos de administración, con la consiguiente dificultad para su cumplimiento por parte de los pacientes; tales inconvenientes pueden obviarse con el uso de formulaciones combinadas en proporción preestablecida. La solución oftálmica que contiene la combinación en proporción fija (CPF) de latanoprost (una prostaglandina) al 0.005 y timolol (un betabloqueante) al 0.5